24 insiders have filed at VRTX since 2023Q3: names, roles, reported stakes, and each person's buying and selling record from SEC Form 3/4/5 filings.
| name | role | reported stake | % of company | buys (3y) | sells (3y) |
|---|---|---|---|---|---|
| Kewalramani Reshma | CEO & President | 98.3k | 0.038% | 2 buys $3.9M | 22 sells $64.0M |
| Sachdev Amit | EVP Chief Patient & Ext Af Off | 65.8k | 0.026% | 16 sells $37.7M | |
| Arbuckle Stuart A | EVP, COO | 63.5k | 0.025% | 6 sells $11.0M | |
| Wagner Charles F JR | EVP, Co & Fo | 47.0k | 0.018% | 9 sells $19.2M | |
| Tatsis Ourania | EVP, Chief Reg. & Quality Off. | 46.8k | 0.018% | 22 sells $16.5M | |
| Sachs Bruce I | Director | 45.0k | 0.018% | 2 buys $1.9M | 6 sells $14.2M |
| Leiden Jeffrey M | Executive Chairman | 35.2k | 0.014% | 27 sells $81.0M | |
| Altshuler David | EVP, Chief Scientific Officer | 34.5k | 0.013% | 15 sells $12.6M | |
| Bozic Carmen | EVP And CMO | 33.1k | 0.013% | 15 sells $22.0M | |
| Liu Joy | EVP And Chief Legal Officer | 22.8k | <0.01% | 1 sells $442k | |
| Atkinson Edward Morrow III | EVP, Chief Technical Ops. Off. | 18.4k | <0.01% | 13 sells $11.6M | |
| Biller Jonathan | EVP And Chief Legal Officer | 13.7k | <0.01% | 12 sells $7.8M | |
| Mckechnie Duncan | EVP, Chief Commercial Officer | 12.5k | <0.01% | 4 sells $4.9M | |
| Bunnage Mark E. | EVP, Chief Scientific Officer | 7.3k | <0.01% | 4 sells $3.0M | |
| Garber Alan M | Director | 6.9k | <0.01% | ||
| Ambrose Kristen | SVP & Chief Accounting Officer | 6.6k | <0.01% | 11 sells $4.4M | |
| Kearney Terrence C | Director | 6.5k | <0.01% | 1 sells $3.5M | |
| Carney Lloyd | Director | 6.3k | <0.01% | ||
| Bhatia Sangeeta N. | Director | 4.3k | <0.01% | 9 sells $1.8M | |
| Mckenzie Diana | Director | 2.4k | <0.01% | ||
| Upadhyay Suketu | Director | 2.4k | <0.01% | ||
| Thornberry Nancy | Director | 2.0k | <0.01% | ||
| Schneider Jennifer | Director | 1.7k | <0.01% | ||
| Lagarde Michel | Director | 1.1k | <0.01% |
Full register at boothcheck.com/insiders/VRTX. Stakes are the newest reported Form 3/4/5 balances (they update only when insiders file). Sales counted include pre-scheduled plan sales, labeled. A filed record, not a forecast. Nothing here is investment advice.